Obsolete Anti-pneumococcal Vaccination Recommendations in the Spanish Guidelines for the Management of Asthma (GEMA 4.0)

La guía española del manejo del asma (GEMA 4.0) está obsoleta en lo que a vacunación antineumocócica se refiere

To the Editor:

The most recent version of the Spanish Guidelines for the Management of Asthma (GEMA 4.0) states in the section on recommendations for vaccination that: “Influenza and pneumococcal vaccination have shown no efficacy in preventing asthma exacerbations. However, since it is a cost-effective strategy, and the risk of complications in chronic patients in high, annual influenza vaccine should be considered in pediatric and adult patients with moderate-to-severe asthma.”

This statement (supported by a reference from the year 2002) omits the recommendation of pneumococcal vaccination, making it obsolete in the light of current knowledge.

Numerous papers, some of which were published by the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) itself, recommend pneumococcal vaccination in asthma patients. Specifically, the consensus document on anti-pneumococcal vaccination in adults with underlying disease, signed by 16 scientific societies, states that “In addition to COPD, asthma is another chronic respiratory disease which appears to act as a risk factor.” Several specific recommendations and recent systematic reviews on pneumococcal vaccination in subjects with respiratory diseases refer to the need to prevent pneumococcal disease in these patients due to their increased risk.

Asthma patients have been reported in various studies to have a higher incidence of invasive pneumococcal disease (IPD), correlating with the degree of asthma severity. A greater risk of developing IPD is seen in the high risk group, defined as asthmatics with 1 or more hospitalizations or visits to the emergency room, long-term use of rescue treatment or oral corticosteroids, or use of beta-agonists ≥3 times during the previous year. A systematic review of IPD in asthma patients concluded that in view of the high risk of these patients, pneumococcal vaccination should be recommended in this population.

Similarly, available data on pneumococcal pneumonia, the most common form of pneumococcal disease in adults, show a significant increase in the incidence and risk of this entity in asthmatics compared to the healthy population. Okapuu et al. calculated the number of asthma patients who needed to be vaccinated (NNV) to prevent 1 case of IPD, using both the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPV23). Assuming a vaccine efficacy of 65%, the NNV ranged between 135 and 839 adults, a number comparable to that found for other diseases considered high-risk for which pneumococcal vaccination with both vaccines is recommended. Moreover, the CAPITA study (clinical efficacy of PCV13 pneumococcal vaccination against pneumococcal pneumonia), with more than 84,000 subjects ≥65 years of age, including patients with asthma and other respiratory diseases, demonstrated that PCV13 is effective for preventing both IPD and pneumococcal pneumonia caused by the vaccine serotypes.

In the light of this evidence, pneumococcal vaccination is currently recommended in asthma patients, preferably with a single dose of PCV13, subsequently followed by PPV23 vaccination. In view of the importance, prestige and clinical utility of the GEMA guidelines, we request a rectification and update of the vaccination section which takes into account the current recommendations summarized in the indication for pneumococcal vaccination in asthma patients, particularly those with severe forms of the disease.

References


Enrique Mascarós, Daniel Ocaña, Federico Martínón-Torres, en nombre de Neumoeexpertos en Prevención

Departament de Salud, Hospital Dr. Peset, Centro de Atención Primaria Fuente de San Luis, Valencia, Spain
Grupo Respiratorio de Atención Primaria, Centro de Salud de Algeciras, Algeciras, Cádiz, Spain
Pediatria Clínica, Infectológica y Traslacional, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain

Corresponding author.
E-mail addresses: enmasba@gmail.com, enmasba@sociedadgrap.com (E. Mascarós).